INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.330
-0.070 (-5.00%)
Apr 29, 2026, 11:34 AM EDT - Market open
INmune Bio Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 35 | 41 | 104 | 203 | 114 | 182 | |
| Market Cap Growth | -79.11% | -59.95% | -48.97% | 78.35% | -37.48% | -21.41% | |
| Enterprise Value | 14 | 15 | 73 | 175 | 72 | 112 | |
| Last Close Price | 1.40 | 1.56 | 4.67 | 11.26 | 6.34 | 10.20 | |
| PS Ratio | 744.39 | 829.46 | 7396.10 | 1309.19 | 304.22 | 1005.53 | |
| PB Ratio | 1.58 | 1.76 | 3.23 | 5.32 | 1.89 | 2.27 | |
| P/TBV Ratio | 1.58 | 1.76 | 6.65 | 9.74 | 2.61 | 2.86 | |
| EV/Sales Ratio | 270.05 | 296.38 | 5207.60 | 1127.89 | 191.85 | 619.14 | |
| Debt / Equity Ratio | 0.04 | 0.04 | 0.01 | 0.27 | 0.26 | 0.19 | |
| Net Debt / Equity Ratio | -1.01 | -1.01 | -0.64 | -0.67 | -0.61 | -0.74 | |
| Net Debt / EBITDA Ratio | 0.77 | 0.77 | - | - | - | - | |
| Net Debt / FCF Ratio | 1.00 | 1.00 | 0.62 | 2.12 | 1.62 | 2.09 | |
| Asset Turnover | 0.00 | 0.00 | 0 | 0.00 | 0.00 | 0.00 | |
| Quick Ratio | 3.48 | 3.48 | 3.09 | 2.07 | 5.55 | 18.43 | |
| Current Ratio | 3.55 | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 | |
| Return on Equity (ROE) | -165.16% | -165.16% | -119.83% | -61.09% | -38.91% | -51.00% | |
| Return on Assets (ROA) | -53.66% | -53.66% | -55.19% | -26.78% | -17.85% | -25.92% | |
| Return on Capital Employed (ROCE) | -129.00% | -129.00% | -131.80% | -77.20% | -36.60% | -30.50% | |
| Earnings Yield | -123.41% | -110.75% | -40.64% | -14.79% | -23.99% | -16.67% | |
| FCF Yield | -63.47% | -56.96% | -32.22% | -5.90% | -19.94% | -15.66% | |
| Buyback Yield / Dilution | -24.13% | -24.13% | -10.92% | -0.30% | -11.14% | -34.55% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.